Clinical Trials
7
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:6
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Not Applicable
1 (14.3%)A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Not Applicable
Not yet recruiting
- Conditions
- Pancreatic Cancer, MetastaticPDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Engeneic Pty Limited
- Target Recruit Count
- 144
- Registration Number
- NCT07049055
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
Phase 1
Completed
- Conditions
- Astrocytoma, Grade IVGlioblastoma
- Interventions
- Drug: EGFR(V)-EDV-Dox
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Engeneic Pty Limited
- Target Recruit Count
- 9
- Registration Number
- NCT02766699
- Locations
- 🇺🇸
John Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Lenox Hill Hospital, Northwell Health, New York, New York, United States
News
No news found